TELA Bio logo
TELA Bio TELA
$ 0.68 1.1%
report update icon

Quarterly report 2026-Q1
added 05-13-2026

TELA Bio Financial Statements 2025-2011 | TELA

Annual Financial Statements TELA Bio

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

32.4 M 19.7 M 131 M 164 M 177 M 185 M 26.1 M - - - - - - - -

Shares

46.9 M 28.5 M 22.9 M 16.3 M 14.5 M 12.9 M 1.77 M - - - - - - - -

Historical Prices

0.69 0.69 5.73 10.1 12.2 14.3 14.9 - - - - - - - -

Net Income

-38.8 M -37.8 M -46.7 M -44.3 M -33.3 M -28.8 M -22.4 M -21.1 M -21.3 M - - - - - -

Revenue

80.3 M 69.3 M 58.5 M 41.4 M 29.5 M 18.2 M 15.4 M 8.27 M 4.24 M - - - - - -

Cost of Revenue

25.6 M 22.4 M 18 M 13.6 M 10.3 M 6.68 M 5.87 M 4.55 M 1.71 M - - - - - -

Gross Profit

54.3 M 46.5 M 40.1 M 27 M 18.8 M 11.2 M 9.27 M 2.94 M 2.53 M - - - - - -

Operating Income

-33.8 M -34.1 M -44.1 M -39 M -29.5 M -25.3 M -19.2 M -17.8 M -16.9 M - - - - - -

Interest Expense

1.29 M 1.42 M 5.22 M 4.05 M 3.6 M 3.56 M 3.61 M 1.8 M 4.56 M - - - - - -

EBITDA

-33.1 M -33.5 M -43.6 M -38.6 M -29.2 M -25.1 M -18.6 M -18.7 M -16.2 M - - - - - -

Operating Expenses

88.1 M 88.2 M 84.2 M 66.1 M 48.3 M 36.5 M 28.4 M 22.9 M 19.5 M - - - - - -

General and Administrative Expenses

15.7 M 14.7 M 14.9 M 13.9 M 12.5 M 10.1 M 6.22 M 4.9 M 4.96 M - - - - - -

All numbers in USD currency

Quarterly Income Statement TELA Bio

2026-Q1 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

57.3 M 45.4 M 45.4 M 45.3 M 39.4 M 24.7 M 24.7 M 24.6 M 24.5 M 24.5 M 23.2 M 19.2 M 19.2 M 16.8 M 14.6 M 14.5 M 14.5 M 14.5 M 14.5 M 14.4 M 14.4 M 14.4 M 11.4 M 11.4 M 11.4 M 298 K 296 K 296 K 296 K 295 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Net Income

-12.3 M -8.6 M -9.92 M -11.3 M - -10.4 M -12.6 M -5.66 M - -11 M -10.8 M -12 M - -10.7 M -12.7 M -10.9 M - -8.27 M -8.26 M -8.14 M - -7.7 M -6.08 M -7.22 M - -4.67 M -5.26 M -5.97 M - -2.81 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Revenue

19.1 M 20.7 M 20.2 M 18.5 M - 19 M 16.1 M 16.6 M - 15.1 M 14.5 M 11.9 M - 11.2 M 10.4 M 8.23 M - 7.65 M 7.56 M 5.88 M - 5.31 M 3.51 M 3.73 M - 3.97 M 3.3 M 3.31 M - 2.21 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Cost of Revenue

6.44 M 6.62 M 6 M 5.91 M - 6 M 4.92 M 5.17 M - 4.57 M 4.2 M 3.92 M - 3.74 M 3.32 M 3.16 M - 2.98 M 2.4 M 2.34 M - 1.95 M 1.35 M 1.45 M - 1.29 M 1.32 M 1.43 M - 769 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Gross Profit

12.5 M 14 M 14.1 M 12.5 M - 12.9 M 11.1 M 11.3 M - 10.4 M 10.2 M 7.9 M - 7.32 M 6.55 M 5 M - 4.6 M 5.09 M 3.46 M - 3.29 M 2.08 M 2.2 M - 2.6 M 1.91 M 1.8 M - 1.37 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

-10.5 M -7.55 M -9.08 M -10.5 M - -9.36 M -11.6 M -4.83 M - -10.2 M -10.4 M -11.3 M - -9.49 M -10.2 M -9.84 M - -7.22 M -7.31 M -7.27 M - -6.86 M -5.17 M -6.5 M - -3.86 M -4.3 M -5.18 M - -2.52 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Interest Expense

366 K 152 K 379 K 479 K - 337 K 301 K 497 K - 558 K 870 K 1.25 M - 1.03 M 934 K 911 K - 922 K 864 K 889 K - 898 K 884 K 879 K - 899 K 914 K 912 K - 309 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA

-10.4 M - - -10.3 M - - - -4.69 M - - - -11.1 M - -9.22 M -10.1 M -9.77 M - -7.05 M -7.19 M -7.2 M - -6.7 M -5.07 M -6.44 M - -3.65 M -4.16 M -5.11 M - -2.13 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Expenses

23 M 21.5 M 23.2 M 23 M - 22.2 M 22.6 M 23.7 M - 20.6 M 20.6 M 19.2 M - 16.8 M 16.8 M 14.8 M - 11.8 M 12.4 M 10.7 M - 10.2 M 7.25 M 8.7 M - 6.46 M 6.21 M 6.98 M - 3.89 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

General and Administrative Expenses

4.17 M 3.95 M 4.13 M 3.84 M - 3.68 M 3.62 M 3.83 M - 3.73 M 3.47 M 3.63 M - 3.53 M 3.63 M 3.46 M - 3.46 M 2.97 M 2.76 M - 2.61 M 2.15 M 2.52 M - 1.21 M 1.2 M 1.32 M - 1.4 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements TELA Bio TELA
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting TELA Bio plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Medical devices industry

Issuer Price % 24h Market Cap Country
Cutera Cutera
CUTR
- -10.19 % $ 1.99 M usaUSA
Myomo Myomo
MYO
$ 0.93 -3.11 % $ 38.9 M usaUSA
EDAP TMS S.A. EDAP TMS S.A.
EDAP
- - $ 162 M franceFrance
GenMark Diagnostics, Inc. GenMark Diagnostics, Inc.
GNMK
- - $ 1.77 B usaUSA
Avinger Avinger
AVGR
- -20.74 % $ 369 K usaUSA
Axonics Modulation Technologies Axonics Modulation Technologies
AXNX
- - $ 3.31 B usaUSA
Eargo Eargo
EAR
- - $ 10.2 M usaUSA
Lianluo Smart Limited Lianluo Smart Limited
LLIT
- 24.59 % $ 44.8 M chinaChina
Allied Healthcare Products Allied Healthcare Products
AHPI
- 3.58 % $ 2.21 M usaUSA
Obalon Therapeutics, Inc. Obalon Therapeutics, Inc.
OBLN
- -5.86 % $ 30.6 M usaUSA
Apollo Endosurgery Apollo Endosurgery
APEN
- - $ 475 M usaUSA
Aziyo Biologics Aziyo Biologics
AZYO
- 1.37 % $ 20.5 M usaUSA
BioSig Technologies BioSig Technologies
BSGM
- 37.08 % $ 85.7 M usaUSA
BIOLASE BIOLASE
BIOL
- -13.19 % $ 166 K usaUSA
Profound Medical Corp. Profound Medical Corp.
PROF
$ 7.24 -0.14 % $ 219 M canadaCanada
AxoGen AxoGen
AXGN
$ 41.37 0.53 % $ 1.91 B usaUSA
Quanterix Corporation Quanterix Corporation
QTRX
$ 3.38 -3.15 % $ 144 M usaUSA
AVITA Medical AVITA Medical
RCEL
$ 4.44 -3.69 % $ 124 M australiaAustralia
Conformis Conformis
CFMS
- - $ 16.4 M usaUSA
Cardiovascular Systems Cardiovascular Systems
CSII
- 0.15 % $ 844 M usaUSA
CryoLife, Inc. CryoLife, Inc.
CRY
- -4.14 % $ 702 M usaUSA
Bruker Corporation Bruker Corporation
BRKR
$ 61.74 -1.86 % $ 9.37 B usaUSA
CHF Solutions, Inc. CHF Solutions, Inc.
CHFS
- 1.15 % $ 34.5 M usaUSA
Smith & Nephew plc Smith & Nephew plc
SNN
$ 32.66 0.31 % $ 28.3 B britainBritain
Soliton, Inc. Soliton, Inc.
SOLY
- -1.42 % $ 435 M usaUSA
Hancock Jaffe Laboratories, Inc. Hancock Jaffe Laboratories, Inc.
HJLI
- -1.98 % $ 98.3 M usaUSA
Itamar Medical Ltd. Itamar Medical Ltd.
ITMR
- 0.03 % $ 1.58 B israelIsrael
Tactile Systems Technology Tactile Systems Technology
TCMD
$ 27.4 -1.23 % $ 627 M usaUSA
Misonix, Inc. Misonix, Inc.
MSON
- - $ 462 M usaUSA
Neovasc Neovasc
NVCN
- - $ 111 M canadaCanada
Dynatronics Corporation Dynatronics Corporation
DYNT
- 14.99 % $ 929 K usaUSA
Tandem Diabetes Care Tandem Diabetes Care
TNDM
$ 18.59 4.67 % $ 1.26 B usaUSA
Intersect ENT, Inc. Intersect ENT, Inc.
XENT
- - $ 955 M usaUSA
Second Sight Medical Products Second Sight Medical Products
EYES
- -0.97 % $ 54.4 M usaUSA
GBS GBS
GBS
- -0.57 % $ 7.12 M usaUSA
ClearPoint Neuro ClearPoint Neuro
CLPT
$ 14.14 -2.68 % $ 400 M usaUSA
IRIDEX Corporation IRIDEX Corporation
IRIX
$ 0.86 -1.95 % $ 14.6 M usaUSA
Avanos Medical Avanos Medical
AVNS
$ 24.99 - $ 1.16 B usaUSA
Viemed Healthcare Viemed Healthcare
VMD
$ 11.65 -2.27 % $ 453 M usaUSA
Varex Imaging Corporation Varex Imaging Corporation
VREX
$ 10.95 -1.62 % $ 453 M usaUSA
Invacare Corporation Invacare Corporation
IVC
- - $ 24.7 M usaUSA
Cytosorbents Corporation Cytosorbents Corporation
CTSO
$ 0.35 -4.32 % $ 21.8 M usaUSA
LENSAR LENSAR
LNSR
$ 5.25 -1.87 % $ 62.8 M usaUSA
Beyond Air Beyond Air
XAIR
$ 5.51 0.92 % $ 45.7 B usaUSA
NanoVibronix NanoVibronix
NAOV
- - $ 1.08 M usaUSA
Xtant Medical Holdings Xtant Medical Holdings
XTNT
$ 0.43 0.14 % $ 60 M usaUSA
NuVasive NuVasive
NUVA
- - $ 2.07 B usaUSA
Natus Medical Incorporated Natus Medical Incorporated
NTUS
- 1.94 % $ 1.05 B usaUSA
Nevro Corp. Nevro Corp.
NVRO
- - $ 217 M usaUSA
Zimmer Biomet Holdings Zimmer Biomet Holdings
ZBH
$ 97.15 1.46 % $ 19.2 B usaUSA